Baytacare Pharmaceutical Co., Ltd. announced that it has on 26 April 2018 resolved to remove Mr. Wang Shaoyan from his position as the chairman of the Board a member and the chairman of each of the nomination committee of Board and the executive committee of the Board and as an authorised representative of the Company with effect from 26 April 2018. Ms. Cui Bingyan has been appointed as the chairman of the Nomination Committee. Ms. Cui Bingyan has been appointed as the chairman of the Executive Committee. Following the removal of Mr. Wang as an Authorised Representative, the Board announced that Mr. Cao Yang, a non-executvie Director, has been appointed as one of the Authorised Representatives for the purposes of Rule 5.24 of the Rules Governing of the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited with effect from 26 April 2018.